These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
881 related articles for article (PubMed ID: 29656345)
1. Update on the Treatment of Early-Stage Triple-Negative Breast Cancer. Sharma P Curr Treat Options Oncol; 2018 Apr; 19(5):22. PubMed ID: 29656345 [TBL] [Abstract][Full Text] [Related]
2. Biology and Management of Patients With Triple-Negative Breast Cancer. Sharma P Oncologist; 2016 Sep; 21(9):1050-62. PubMed ID: 27401886 [TBL] [Abstract][Full Text] [Related]
3. The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics. Anders CK; Abramson V; Tan T; Dent R Am Soc Clin Oncol Educ Book; 2016; 35():34-42. PubMed ID: 27249684 [TBL] [Abstract][Full Text] [Related]
4. Triple-negative breast cancer: advancements in characterization and treatment approach. Hurvitz S; Mead M Curr Opin Obstet Gynecol; 2016 Feb; 28(1):59-69. PubMed ID: 26694831 [TBL] [Abstract][Full Text] [Related]
6. Optimizing chemotherapy in triple-negative breast cancer: the role of platinum. Telli M Am Soc Clin Oncol Educ Book; 2014; ():e37-42. PubMed ID: 24857126 [TBL] [Abstract][Full Text] [Related]
7. Germline mutations in DNA repair genes may predict neoadjuvant therapy response in triple negative breast patients. Spugnesi L; Gabriele M; Scarpitta R; Tancredi M; Maresca L; Gambino G; Collavoli A; Aretini P; Bertolini I; Salvadori B; Landucci E; Fontana A; Rossetti E; Roncella M; Naccarato GA; Caligo MA Genes Chromosomes Cancer; 2016 Dec; 55(12):915-924. PubMed ID: 27328445 [TBL] [Abstract][Full Text] [Related]
8. Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy. Jin J; Zhang W; Ji W; Yang F; Guan X Cancer Biol Ther; 2017 Jun; 18(6):369-378. PubMed ID: 28494179 [TBL] [Abstract][Full Text] [Related]
9. BRCA Mutational Status is a Promising Predictive Biomarker for Platinum- based Chemotherapy in Triple-Negative Breast Cancer. Tazzite A; Jouhadi H; Benider A; Nadifi S Curr Drug Targets; 2020; 21(10):962-973. PubMed ID: 32013831 [TBL] [Abstract][Full Text] [Related]
10. Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer. Telli ML; Stover DG; Loi S; Aparicio S; Carey LA; Domchek SM; Newman L; Sledge GW; Winer EP Breast Cancer Res Treat; 2018 Aug; 171(1):21-31. PubMed ID: 29736741 [TBL] [Abstract][Full Text] [Related]
11. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review. Costa RLB; Han HS; Gradishar WJ Breast Cancer Res Treat; 2018 Jun; 169(3):397-406. PubMed ID: 29417298 [TBL] [Abstract][Full Text] [Related]
12. Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer. Lin PH; Chen M; Tsai LW; Lo C; Yen TC; Huang TY; Chen CK; Fan SC; Kuo SH; Huang CS Cancer Sci; 2020 Apr; 111(4):1375-1384. PubMed ID: 31958182 [TBL] [Abstract][Full Text] [Related]
13. Biomarkers of DNA Repair and Related Pathways: Significance of Treatment in Triple-Negative Breast Cancer. Guo W; Lin L; He X; He F; Wang C; Chen N; Wang Y Crit Rev Oncog; 2017; 22(5-6):427-437. PubMed ID: 29604922 [TBL] [Abstract][Full Text] [Related]
14. Tailoring adjuvant chemotherapy regimens for patients with triple negative breast cancer. Stover DG; Winer EP Breast; 2015 Nov; 24 Suppl 2():S132-5. PubMed ID: 26255198 [TBL] [Abstract][Full Text] [Related]
15. A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors. Evans KW; Yuca E; Akcakanat A; Scott SM; Arango NP; Zheng X; Chen K; Tapia C; Tarco E; Eterovic AK; Black DM; Litton JK; Yap TA; Tripathy D; Mills GB; Meric-Bernstam F Clin Cancer Res; 2017 Nov; 23(21):6468-6477. PubMed ID: 29093017 [No Abstract] [Full Text] [Related]
16. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer. Isaacs J; Anders C; McArthur H; Force J Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085 [TBL] [Abstract][Full Text] [Related]
17. Homologous recombination deficiency in triple negative breast cancer. Belli C; Duso BA; Ferraro E; Curigliano G Breast; 2019 Jun; 45():15-21. PubMed ID: 30818144 [TBL] [Abstract][Full Text] [Related]
18. High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients. Rashid MU; Muhammad N; Bajwa S; Faisal S; Tahseen M; Bermejo JL; Amin A; Loya A; Hamann U BMC Cancer; 2016 Aug; 16(1):673. PubMed ID: 27553291 [TBL] [Abstract][Full Text] [Related]
19. Prevalence of Germline Mutations in Genes Engaged in DNA Damage Repair by Homologous Recombination in Patients with Triple-Negative and Hereditary Non-Triple-Negative Breast Cancers. Domagala P; Jakubowska A; Jaworska-Bieniek K; Kaczmarek K; Durda K; Kurlapska A; Cybulski C; Lubinski J PLoS One; 2015; 10(6):e0130393. PubMed ID: 26083025 [TBL] [Abstract][Full Text] [Related]
20. A large collection of integrated genomically characterized patient-derived xenografts highlighting the heterogeneity of triple-negative breast cancer. Coussy F; de Koning L; Lavigne M; Bernard V; Ouine B; Boulai A; El Botty R; Dahmani A; Montaudon E; Assayag F; Morisset L; Huguet L; Sourd L; Painsec P; Callens C; Chateau-Joubert S; Servely JL; Larcher T; Reyes C; Girard E; Pierron G; Laurent C; Vacher S; Baulande S; Melaabi S; Vincent-Salomon A; Gentien D; Dieras V; Bieche I; Marangoni E Int J Cancer; 2019 Oct; 145(7):1902-1912. PubMed ID: 30859564 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]